Intact raises $4.7M to further its PAD device work

Intact Vascular raised nearly $4.7 million of an anticipated $9 million funding round, according to a regulatory filing. The company did not disclose details. In October, the Wayne, PA-based operation concluded enrollment in a 138-patient multicenter study testing its Tack-It endovascular stapler system in the superficial femoral and popliteal arteries after angioplasty for peripheral artery disease. A $15.5 million Series A round completed in September 2012 helped back the just-completed trial. Tack-It is a permanent catheter implant with four self-expanding tacks intended to optimize angioplasty by creating tissue apposition to smooth the arterial lumen. The device has had a CE mark since April 2012. Quaker Partners and H.I.G. BioVentures are among Intact's investors. Filing | Coverage

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.